Correction to: Antimicrobial Drugs Encapsulated in Fibrin Nanoparticles for Treating Microbial Infested Wounds (Pharmaceutical Research, (2014), 31, 5, (1338-1351), 10.1007/s11095-013-1254-6);Antimicrobial drugs encapsulated in fibrin nanoparticles for treating microbial infested wounds

Pharmaceutical Research

Volumn 31, Issue 5, 2014, Pages 1338-1351

  Alphonsa, B Maria ^a   Sudheesh Kumar, P T ^a   Praveen, G ^a   Biswas, Raja ^a   Chennazhi, K P ^a   Jayakumar, R ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

ciprofloxacin; drug delivery; fibrin; fluconazole; nanoparticles

Indexed keywords

CIPROFLOXACIN; FIBRIN; FIBRIN NANOPARTICLE; FIBRINOGEN; FLUCONAZOLE; NANOPARTICLE; THROMBIN; UNCLASSIFIED DRUG; WATER OIL CREAM; ANTIINFECTIVE AGENT;

ALKALINITY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL VIABILITY; CONTROLLED STUDY; CROSS LINKING; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SYNTHESIS; VASCULARIZATION; WOUND HEALING; WOUND INFECTION; DRUG EFFECTS; INFRARED SPECTROSCOPY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SCANNING ELECTRON MICROSCOPY; WOUNDS AND INJURIES;

ANTI-INFECTIVE AGENTS; CANDIDA ALBICANS; ESCHERICHIA COLI; FIBRIN; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STAPHYLOCOCCUS AUREUS; WOUNDS AND INJURIES;

EID: 84902267132     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-019-2617-4     Document Type: Erratum

References (31)

1. Praveen G, Sreerakha PR, Menon D, Nair SV, Chennazhi KP. Fibrin nanoconstructs: a novel processing method and their use as controlled delivery agents. Nanotechnology. 2012;23(9):095102.
2. Frank A, Eric P, Linda KM. Factors affecting the clearance and bio distribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-15.
3. Lilian EV, Manoor A. Multi-functional polymeric nanoparticle for tumor- targeted drug delivery. Expert Opin Drug Deliv. 2006;3(2):205-16.
4. Wim HDJ, Paul JAB. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133-49.
5. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894-904.
6. Breen A, O'brien T, Pandit A. Fibrin as a delivery system for therapeutic drugs and biomolecules. Tissue Eng B Rev. 2009;15(2):201-14.
7. Nehls V, Herrmann R. The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration. Microvasc Res. 1996;51(3):347-61.
8. Nehls V, Herrmann R, Huhnken M. Guided migration as novel mechanism of capillary network remodelling is regulated by basic fibroblast growth factor. Histochem Cell Biol. 1998;109(4):319-29.
9. Paul AJ, Jessamine PW, John WW. Fibrin gels and their clinical and bioengineering applications. J R Soc Interface. 2009;66(30):1-10.
10. Dresdale A, Rose EA, Jeevavavdam V, Reematsma K, Bowman FO, Malm JR. Preparation of fibrin glue from single-donor fresh- frozen plasma. Surgery. 1985;97(6):750-4.
11. Mol A, Van LMI, Dam CG, Neuenschwander S, Hoerstrup SP, Baaijens FP, et al. Fibrin as a cell carrier in cardiovascular tissue engineering applications. Biomaterials. 2005;26(16):3113-21.
12. Fang H, Peng S, Chen A, Li F, Ren K, Hu N. Biocompatibility studies on fibrin glue cultured with bone marrow mesenchymal stem cells in vitro. J Huazhong Univ Sci Technol Med Sci. 2004;24(3):272-4.
13. Ho W, Tawil B, Dunn JC, Wu BM. The behavior of human mesenchymal stem cells in 3D fibrin clot: dependence on fibrinogen concentration and clot structure. Tissue Eng. 2006;12(6):1587-95.
14. Boyce ST, Holder IA, Supp AP, Warden GD, Greenhalgh DG. Delivery and activity of antimicrobial drugs from human fibrin sealant. J Burn Care Rehabil. 1994;15(3):251-5.
15. Schwarz R, Penk A, Pittrow L. Administration of fluconazole in children below 1 year. Mycoses. 1998;42(1-2):3-16.
16. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89(3):219-29.
17. Masterton RG. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents. 2009;33(2):105-10.
18. Dissemond J, Schmid EN, Esser S, Witthoff M, Goos M. Bakterielle kolonisation chronischer wunden. Hautarzt. 2004;55:280-8.
19. Percival SL, Bowler PG, Russel D. Bacterial resistance to silver in wound care. J Hosp Infect. 2005;60(1):1-7.
20. Zhang L, Pornpattananangku D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010;17(6):585-94.
21. Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicaemia: a prospective randomised trial. Pediatr Infect Dis J. 1996;15(12):1107-12.
22. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986;30(3):444-6.
23. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med. 2002;8(2):76-81.
24. Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr. 2005;147(2):135-41.
25. Paolo M, Ilaria S, Lorenza P, Lidia D, Cristiana M, Gennaro V, et al. A multi-center randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356(24):2483-95.
26. Wade KC, Benjamin DK, Kaufman DA, Ward RM, Smith PB, Jayaraman B, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28(8):717-23.
27. Zhang G, Wang X, Wang Z, Zhang J, Suggs L. A PEGylated fibrin patch for mesenchymal stem cell delivery. Tissue Eng. 2006;12(1):9-19.
28. Seetharaman S, Natesan S, Stowers RS, Mullens C, Baer DG, Suggs LJ, et al. A PEGylated fibrin-based wound dressing with antimicrobial and angiogenic activity. Acta Biomater. 2011;7(7):2787-96.
29. Suvakanta D, Padala NM, Lilakanta N, Prasanta C. Kinetic Modeling on drug release from controlled drug delivery system. Acta Pol Pharma Drug Res. 2010;67(3):217-23.
30. Davies BI, Maesen FP. Drug interactions with quinolones. Rev Infect Dis. 1989;11(15):1083-90.
31. Williams RJ, Attia E, Wickiewicz TL, Hannafin JA. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med. 2000;28(3):364-9.